RxDoctor Payments DataLook up a doctor →

Drew Heiple, MD

Nephrology · Russellville, ARNPI 1376665646

Payments from drug & device makers

$236,464in general payments, 2019–2025

Across 542 payments — averaging $436.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$162K
  • Novo Nordisk$66K
  • Amgen$3K
  • Mozarc Medical US LLC$2K
  • Travere Therapeutics, Inc.$634
  • Bayer$444
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$207,50388%
  • Travel & lodging$18,4958%
  • Food & beverage$9,9574%
  • Education$5090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$236,464 in reported general payments places this provider in the 95th percentile of 85 nephrology providers in Arkansas.

See all nephrology providers in Arkansas

Medicare billing

Part B allowed, 2024
$320,555
Medicare patients
592
Services billed
2,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol194$145,202
VelphoroSucroferric Oxyhydroxide36$93,206
OzempicSemaglutide41$48,682
JardianceEmpagliflozin41$27,680
LokelmaSodium Zirconium Cyclosilicate37$25,647
ProsolParenteral Amino Acid 20% No.1117$22,302
Sevelamer Carbonate59$18,021
VeltassaPatiromer Calcium Sorbitex14$13,753
XareltoRivaroxaban12$10,726
NexiumEsomeprazole Magnesium12$7,226
Calcium Acetate45$2,259
Bumetanide45$2,047
Potassium Chloride42$1,432
Clonidine15$1,373
Nifedipine ErNifedipine64$1,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma, Nexium$161,876$178,076243 claims
Fresenius USA Marketing, Inc.Velphoro$217$93,20636 claims
Novo NordiskOzempic$66,331$48,68241 claims
Boehringer IngelheimJardiance$50$27,68041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 85 nephrology providers in Arkansas.

Other nephrology in Russellville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →